Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
Women are more likely than men not to take their diabetes medication as prescribed in an effort to control prescription drug costs, as are adults under age 65, according to a report published this month by the Centers for Disease Control and Prevention (CDC).
The August data brief used data from the 2017-2018 National Health Interview Survey (NHIS), looking who was more likely to ration diabetes medications as a cost-savings measure during the past 12 months.
Despite a recent shift to lower-cost options as the first line of diabetes therapy, the burden of high prescription drug costs remains a public health concern, the CDC noted. The price of insulin has been the topic of numerous hearing on Capitol Hill, and some companies have responded by introducing authorized generics or by capping prices as the wait for cheaper biosimilar insulin continues. Rationing of insulin and other supplies needed to manage diabetes is known to be a worldwide problem.
Last year, diabetes medications ranked sixth out of the top 20 therapeutic classes of dispensed prescriptions, accounting for 214 million prescriptions. In 2017, the annual per capita expense for outpatient diabetes medication was almost $5000, the CDC said.
Among adults with diagnosed diabetes, women (14.9%) were more likely than men (11.6%) not to take their medication as prescribed, although they were as likely to ask their doctor for a lower-priced medication (25.5% vs 23.4%).
The survey also found that uninsured adults aged 18 to 64 years were more likely than those with private insurance or Medicaid to not take their medication as prescribed and to ask their doctor for a lower-cost drug. Almost 36% of the uninsured did not take medication as prescribed, compared with 14% of those with private health insurance and nearly 18% of those with Medicaid coverage. Likewise, 42.6% of uninsured adults were more likely to seek out cheaper prescriptions, compared with patients who had private coverage (25.7%) or Medicaid coverage (18.8%).
Younger adults were more likely than those aged 65 and over to not take their medication as prescribed (17.9% and 7.2%, respectively) and to ask their doctor for a lower-cost drug (26.3% and 21.9%, respectively).
Among adults aged 65 and over, the percentage who did not take their diabetes medication as prescribed did not vary significantly by coverage type (private coverage, Medicare and Medicaid, Medicare Advantage, traditional fee-for-service Medicare only, other coverage, or no insurance), ranging from 6.2% for those with private insurance to 9.2% for those with traditional Medicare.
Within this group, the percentage of patients who asked their doctor for a lower-cost diabetes medication was lowest among those with Medicare and Medicaid coverage (13.0% each) compared with private (26.1%), Medicare Advantage (25.8%), or Medicare only (22.7%) coverage.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.